6117 |
PREVENT Trial: Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque |
Jung-Min Ahn |
Apr. 19. 24 |
6116 |
OCTIVUS Trial: OCT- vs. IVUS-guided PCI in All-comer PCI |
Do-Yoon Kang |
Apr. 19. 24 |
6115 |
OCTOBER Trial: OCT- vs. Angiography-guided PCI in Complex Bifurcation Lesions |
Niels Ramsing Holm |
Apr. 19. 24 |
6114 |
ILUMIEN IV Trial: OCT- vs. Angiography-guided PCI in High-Risk PCI |
Ziad A. Ali |
Apr. 19. 24 |
6113 |
Following BEST-CLI and BASIL-2: How to ¡°Best¡± Serve Critical Limb Threatening Ischemia? |
Lawrence A. Garcia |
Apr. 19. 24 |
6112 |
Zilver PTX (Paclitaxel-Coated Stent): Transparency, Data, and Patient Safety |
Hiroyoshi Yokoi |
Apr. 19. 24 |
6111 |
Expert Thoughts on Drug-Eluting Resorbable Scaffolds on Peripheral Interventions: Dreaming or Still Caution? |
William A. Gray |
Apr. 19. 24 |
6110 |
Stentless TEVAR for Chronic Type IIIB Aortic Dissection |
Suk-Won Song |
Apr. 19. 24 |
6109 |
Is TEVAR Safe and Durable in a Long-Term? |
Han Cheol Lee |
Apr. 19. 24 |
6108 |
Is EVAR Safe and Durable in a Long-Term? |
Young-Guk Ko |
Apr. 19. 24 |